Onconova Therapeutics, Inc. Form 8-K November 06, 2014

# TINITED OF ATEC

	UNITED STATES	
SECURITIES	S AND EXCHANGE CO	OMMISSION
	Washington, DC 20549	
	FORM 8-K	
PURSU	CURRENT REPORT  JANT TO SECTION 13 OR 15(d) OF	тне
	CURITIES EXCHANGE ACT OF 19	
Date of Re	port (Date of earliest event reported): <b>Novembe</b>	r 6, 2014
	conova Therapeutics, In	
<b>Delaware</b> (State or Other Jurisdiction	<b>001-36020</b> (Commission	<b>22-3627252</b> (I.R.S. Employer
of Incorporation or Organization)	File Number)	Identification No.)

375 Pheasant Run Newtown, PA 18940 (267) 759-3680

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant s Principal Executive Offices)

#### Not Applicable

	(Former name or former address, if changed since last report)
	opropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of g provisions:
0	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
0	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
0	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
0	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Item 7.01. Regulation FD Disclosure.

On November 6, 2014, Onconova Therapeutics, Inc. (the Company) issued a press release announcing that ten abstracts related to the Company s products, clinical trials and research were accepted for presentation at the 56th American Society of Hematology (ASH) Annual Meeting in San Francisco, California, to be held on December 6-9, 2014. All ten presentations are listed in the press release, which is attached hereto as Exhibit 99.1 and incorporated herein by reference.

On November 6, 2014, in connection with such presentations, ASH released such abstracts to the public by posting them on its website. The full text of each of the ten abstracts are attached to this Current Report on Form 8-K as Exhibits 99.2 through 99.11 and are incorporated herein by reference.

The information in Item 7.01 of this Form 8-K, and the related exhibits, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act ) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

#### Item 9.01 Financial Statements and Exhibits.

#### (d) Exhibits.

Exhibit No.	Description
99.1	Press release issued by the Company dated November 6, 2014.
99.2	Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-risk Myelodysplastic Syndrome (HR-MDS) After Failure of Hypomethylating Agents (HMAs)
99.3	Relationship of Bone Marrow Blast (BMBL) Response to Overall Survival (OS) in Patients with Higher-risk Myelodysplastic Syndrome (HR-MDS) Treated with Rigosertib After Failure of Hypomethylating Agents (HMAs)
99.4	Mutational Profile and Karyotypic Abnormalities of a Cohort of Clinical Trial Patients with Higher-risk Myelodysplastic Syndromes (MDS) Following Failure of Hypomethylating Agents (HMAs): Impact on Response to Rigosertib Therapy
99.5	A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
99.6	An in Vitro Platform to Dissect Drug Responsiveness in Refractory Anemia with Ringed Sideroblasts (RARS)
99.7	Incidence and Treatment of Myelodysplastic Syndrome in the US: Treatment Approaches, Optimization of Care and the Need for Additional Therapeutic Agents
99.8	Cost Effectiveness of Treatments after Failure of a First-Line Hypomethylating Agent in Myelodysplastic Syndromes (MDS)

99.9	Treatment Patterns Among Patients with Myelodysplastic Syndromes: Observations of 1st-Line Therapy, Discontinuation and the Need of Additional Therapies
99.10	Healthcare Resource Utilization and Costs Among Patients with Myelodysplastic Syndrome Who Failed 1st-Line Therapy
99.11	Weighted Gene Co-Expression Network Analysis (WGCNA) Identifies Highly Proliferative Myeloma Subgroup Responsive to CDK4/ARK5 Inhibition

#### **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 6, 2014 Onconova Therapeutics, Inc.

By: /s/ AJAY BANSAL

Name: Ajay Bansal Title: Chief Financial Officer

3

## EXHIBIT INDEX

Exhibit No.	Description	
99.1	Press release issued by the Company dated November 6, 2014.	
99.2	Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-risk Myelodysplastic Syndrome (HR-MDS) After Failure of Hypomethylating Agents (HMAs)	
99.3	Relationship of Bone Marrow Blast (BMBL) Response to Overall Survival (OS) in Patients with Higher-risk Myelodysplastic Syndrome (HR-MDS) Treated with Rigosertib After Failure of Hypomethylating Agents (HMAs)	
99.4	Mutational Profile and Karyotypic Abnormalities of a Cohort of Clinical Trial Patients with Higher-risk Myelodysplastic Syndromes (MDS) Following Failure of Hypomethylating Agents (HMAs): Impact on Response to Rigosertib Therapy	
99.5	A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)	
99.6	An in Vitro Platform to Dissect Drug Responsiveness in Refractory Anemia with Ringed Sideroblasts (RARS)	
99.7	Incidence and Treatment of Myelodysplastic Syndrome in the US: Treatment Approaches, Optimization of Care and the Need for Additional Therapeutic Agents	
99.8	Cost Effectiveness of Treatments after Failure of a First-Line Hypomethylating Agent in Myelodysplastic Syndromes (MDS)	
99.9	Treatment Patterns Among Patients with Myelodysplastic Syndromes: Observations of 1st-Line Therapy, Discontinuation and the Need of Additional Therapies	
99.10	Healthcare Resource Utilization and Costs Among Patients with Myelodysplastic Syndrome Who Failed 1st-Line Therapy	
99.11	Weighted Gene Co-Expression Network Analysis (WGCNA) Identifies Highly Proliferative Myeloma Subgroup Responsive to CDK4/ARK5 Inhibition	

4